Articles tagged with Brain Tumors
Researchers developed a biosensor that can detect brain cancer from minute blood samples using surface-enhanced Raman spectroscopy. The test distinguishes primary brain tumors from secondary tumors and predicts tumor location within the brain with high accuracy.
Researchers have identified a small molecule drug, SHP656, that can target the circadian clock proteins responsible for glioblastoma's recurrence and spread. The drug has shown promise in reducing cancer stem cell growth without harming normal stem cells.
A potential new treatment for glioblastomas, a deadly form of brain tumor, is being researched using the medication letrozole. Studies have shown that letrozole can be effective in killing tumor cells and reaching target tissue safely.
Researchers have discovered that group 3 and group 4 medulloblastoma arise from the rhombic lip, a structure present in early cerebellum development. This finding helps better understand the biology of the disease and develops new research models to guide therapeutic targets.
Researchers have discovered that a type of pediatric brain tumour, medulloblastoma, develops in a pre-malignant form during human fetal brain development. This finding suggests that medulloblastomas could be preventable by identifying the genetic variations that cause them and acting before they develop.
A new biomarker called SPRIGHTLY could distinguish between two aggressive types of brain tumors in children: Group 3 and Group 4 medulloblastomas. The biomarker is highly expressed in Group 4 medulloblastomas, which have a poorer prognosis.
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers have made significant breakthroughs in understanding the molecular mechanisms of supratentorial ependymoma, a rare and aggressive form of childhood brain cancer. By targeting the Hedgehog signaling pathway and primary cilia formation, scientists discovered new potential treatments that overcame resistance to existing drugs.
A new study found that high-grade gliomas remodel the surrounding brain environment to protect tumour cells and hide them from the body's defences. Lower grade tumours often develop a new mutation allowing rapid cell division, potentially progressing to higher grade forms.
Researchers have developed an immunity-boosting postoperative treatment that could prevent glioblastoma relapse by targeting cancer stem cells with nanoparticles. The injectable gel promotes the cancer-killing immune response and reduces toxic side effects.
Researchers at University of Bristol developed mathematical models to assess biomarkers for detecting glioblastomas, a type of brain cancer. The study found that lowering the current biomarker threshold could lead to earlier detection using blood tests.
Virginia Tech scientists have developed a novel 3D tissue-engineered model of the glioblastoma tumor microenvironment to learn why tumors return and what treatments will be most effective. The model accounts for cell types, fluid flow, and other aspects of the actual tumor environment, allowing for easy testing of drug therapies.
Researchers discover gene AVIL responsible for deadly brain tumor also causes two forms of childhood cancer, rhabdomyosarcoma. Blocking AVIL activity prevents formation of the disease in lab samples and mouse models.
Researchers have found that targeting the GLI protein is more effective in treating medulloblastoma than previously thought, with a potential breakthrough in reducing tumor aggressiveness. The study's findings offer new hope for improving treatment outcomes and survival rates for children with this rare cancer.
Researchers at Massachusetts General Hospital have developed a blood test that can detect multiple mutations associated with brain cancer, including EGFRvIII. The test showed high sensitivity and specificity, making it a powerful tool for diagnosing gliomas and monitoring tumor progression.
A team at Baylor College of Medicine found that Sox9, a well-known transcription factor, affects brain tumor growth differently in various tumor types. The study revealed distinct mechanisms for regulating epigenetic patterns, which may lead to new possibilities for developing novel therapies.
Researchers uncovered details about the underlying biology of melanoma brain metastases, including genomics, immunology, and spatial organization. The study found that melanoma brain metastases are more chromosomally unstable than other types of metastases, with potential therapeutic targets in reduced chromosomal instability.
A study by Michigan Medicine researchers has identified oncostreams, highly active cells connected to brain tumor growth and invasion. The team found that eliminating Collagen 1 production from tumor cells reduces tumor aggressive behavior. This discovery could lead to novel therapeutic targets for treating lethal brain tumors.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
A novel somatostatin-receptor targeting peptide has shown excellent imaging in patients with meningiomas, identifying previously undetected lesions. The new agent offers significant logistical advantages, including a longer half-life and large-scale production capabilities.
A proteomic study of 2,002 tumors identified 11 distinct molecular subtypes across 14 tissue-based cancer types, including breast, lung, and brain cancers. These subtypes provide new insights into the deregulated pathways and processes in tumors that make them cancerous.
A novel BRAF inhibitor, C1a, has been developed to cross the blood-brain barrier and treat melanoma brain metastasis. The study found that C1a triggered robust responses in patient-derived models and outperformed approved BRAF inhibitors, achieving significant increases in survival rates.
A team of MIT researchers has developed drug-carrying nanoparticles that can efficiently penetrate the brain and kill glioblastoma cells. Using a human tissue model, they showed that the particles could get into tumors and deliver chemotherapy drugs, including cisplatin, which effectively killed tumor cells.
A meta-analysis published in The Lancet Oncology suggests that targeted radiation therapy, which spares healthy brain tissue, is equitable to whole brain radiation therapy for patients with small cell lung cancer and brain metastases. This approach may improve their care experience with fewer negative cognitive consequences.
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
Researchers discovered that neurons carrying a mutation in the Nf1 gene are hyperexcitable and suppressing this hyperactivity with lamotrigine stops tumor growth in mice. The study provides an explanation for why some people with NF1 lack optic gliomas or neurofibromas, highlighting the critical role of neurons in tumor biology.
Researchers have developed a novel therapeutic strategy for treating glioblastoma using allogenic stem cells that can target and kill tumor cells. The therapy demonstrated profound efficacy in preclinical models, with 100% of mice living over 90 days after treatment.
Researchers are developing a novel MRI nanotechnology that targets specific markers in solid tumours, including high-grade brain cancers. The new imaging technology has shown promising preclinical results and is set to be tested in a first-in-human clinical trial.
The new center aims to advance a groundbreaking combination of focused ultrasound and cancer immunotherapy, potentially revolutionizing cancer treatment. The partnership will focus on overcoming existing limitations of immunotherapy and expanding treatment options for various types of cancer.
The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.
A new study from McGill University finds that people living near regions prone to wildfires may have a higher incidence of lung cancer and brain tumors. Exposure to carcinogenic wildfire pollutants on a chronic basis increases the risk of certain cancers, according to researchers.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
A study from the University of Pittsburgh found that methionine restriction can slow down the growth of difficult-to-treat brain tumors in children, known as diffuse midline gliomas. The researchers discovered that these tumors are uniquely dependent on methionine, an amino acid, and that depleting it can repress cancer cell growth.
City of Hope researchers present new developments in cell therapy for acute myeloid leukemia and non-small cell lung cancer. A novel smoking cessation program increases patient desire to quit with personalized counseling.
Researchers have created a Russian-language protocol for functional magnetic resonance imaging (fMRI) to map individual language areas before neurosurgical operations. The study successfully validated the protocol in a control group, showing its ability to comprehensively map brain regions and reveal lateralisation of language function.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Researchers develop innovative non-contact agitation technology to assess motility and invasive capacity of cancer cells in tissue sections. The study reveals significant increases in Rac/Cdc42 activity in tumor areas, with stronger correlations found in advanced cancer stages.
Researchers collected hundreds of cerebrospinal fluid samples from patients with Diffuse Midline Glioma, tracking changes in cell-free tumor DNA over time. The findings suggest that this method could provide data about tumors sooner than MRIs alone, allowing clinicians to address aggressive brain cancer more effectively.
Researchers developed a computational approach called CellTrek to combine parallel gene-expression profiling methods, creating spatial maps at single-cell resolution. The tool provides detailed information on individual cell types' location within tissues, enabling unique biological insights.
Researchers have found that immune checkpoint inhibitors like pembrolizumab can slow disease progression in patients with high-grade meningiomas. The study showed that nearly half of all patients were alive and without evidence of disease progression for at least 6 months after treatment.
Research led by Adam Green, MD, shows that the youngest patients with brain tumors (ages 0-3 months) have about half the five-year survival rate as children ages 1-19. The study analyzed population-based data for almost 14,500 children and found significantly poorer outcomes among the youngest patients.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
Researchers at Johns Hopkins Medicine discovered 110 genes, circular RNAs, lipids and metabolites that differ between medulloblastoma patients' cerebrospinal fluid and healthy controls. These findings provide proof of principle for novel biomarkers to detect and track the disease.
Researchers have developed a low-cost, easy-to-use focused ultrasound device that can precisely target the mouse brain. The $80 device, created using a 3D printer, has been shown to achieve sub-millimeter targeting accuracy and improve drug delivery outcome.
Researchers at IBiS have developed a new treatment that completely eliminated glioblastoma tumors in animal models, offering a new therapeutic option against this aggressive disease. The therapy combines the use of ADI-PEG20 with focal brain radiotherapy and has shown promising results without side effects.
Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.
Four IIT researchers have been awarded €150,000 each from the European Research Council to develop groundbreaking technologies addressing health challenges, such as tumours, blindness, and amputations. Their projects aim to substitute critical raw materials in electronics and create multisensory systems for visually impaired infants.
Researchers developed a method called 6mASCOPE that measures DNA tagging system accuracy and distinguishes bacterial from human DNA. The study found high levels of methylation in plant, fly, mouse, and human cells, but mostly attributed to contamination.
Scientists at University College London have developed a novel cancer therapy using magnetic seeds guided by an MRI scanner to heat and destroy tumours. The therapy, called MINIMA, has the potential to precisely treat hard-to-reach cancers with minimal side effects.
A study led by RCSI researchers found that almost half of tumours with metastatic breast cancer in the brain have changes in DNA repair pathways, making them vulnerable to PARP inhibitor drugs. This discovery opens up potential novel treatment strategies for patients with limited targeted therapy options.
Breakthrough research reveals Tuberous Sclerosis Complex arises from human-specific progenitor cells, explaining its pathology. Human-derived cerebral organoid models shed light on complex brain development and potential mechanisms for other diseases.
A new study by WVU researcher William Walker found that the blood-brain barrier is dynamic and more receptive to chemotherapy at night. This could lead to better treatment outcomes for patients with brain metastasis.
A UC researcher is leading three projects to study the genetic workings of deadly pediatric brain tumors, including DIPG. The goal is to understand how genes regulate blood vessels and develop more effective treatments. Researchers are also exploring a new drug that targets a specific genetic mutation.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.
Researchers found that zika virus injections destroyed brain tumors in mice and reduced tumor size in cerebral organoids, with immune cells alerting the system to its existence. This approach opens up prospects for virotherapy treatment of central nervous system tumors.
A phase 1 clinical trial found that the DNA methylome of aggressive brain tumors can be reprogrammed with L-methylfolate, a folic acid-like drug. The treatment showed improved median overall survival in patients with recurrent glioblastoma, paving the way for future epigenetic studies and potential immunotherapy combinations.